Description

Epitumomab Cituxetan is a monoclonal antibody-based radiopharmaceutical agent, specifically a murine IgG1 monoclonal antibody conjugated to the β-emitting radioisotope Yttrium-90. This compound is of significant interest in targeted radiotherapy, offering a mechanism for the precise delivery of cytotoxic radiation to specific cell populations. It is primarily utilized in advanced research and development within the fields of oncology and nuclear medicine, particularly for the treatment of non-Hodgkin's lymphoma and other hematological malignancies.

Application

• Targeted Radiotherapy for Hematological Cancers: Primary application in the research and treatment of B-cell non-Hodgkin's lymphoma (NHL).
• Preclinical Oncology Research: Used as a model radioconjugate in studies investigating antibody-directed radiation therapy.
• Nuclear Medicine Development: Serves as a key reference standard in the development and validation of new radioimmunotherapy (RIT) protocols.
• Pharmacokinetic and Biodistribution Studies: Essential for research analyzing the in vivo behavior, targeting efficiency, and clearance of antibody-radionuclide complexes.
• Dosimetry and Treatment Planning: Used in research to calculate radiation dose delivery to tumors and critical organs.
• Quality Control and Regulatory Submissions: Acts as a critical reference material for analytical method development and batch release testing in pharmaceutical manufacturing.

Basic Information

Product Name	Epitumomab Cituxetan
CAS No.	263547-71-3
Molecular Formula	C6480H10006N1736O2016S42 (Approximate for antibody component. The full structure includes the Yttrium-90 chelate.)
Molecular Weight	>150 kDa (Approximate, varies with glycosylation and radiolabeling)
Synonyms	Yttrium Y 90 Epitumomab Cituxetan; Y-90 Epitumomab Cituxetan; 90Y-Epitumomab Cituxetan; Anti-CD22 Monoclonal Antibody-Yttrium Y90 Conjugate; Immunoconjugate 90Y-hLL2; hLL2 (Monoclonal Antibody); Monoclonal Antibody hLL2, Yttrium-90 Labeled; Radioimmunoconjugate hLL2/Y-90
EINECS	Contact for details

Quality Control

Our Epitumomab Cituxetan is produced and handled under strict quality systems suitable for research and development use. Each batch is supported by comprehensive analytical data to ensure identity, purity, and radiochemical stability. Certificates of Analysis (COA) are provided, detailing parameters such as radiochemical purity, immunoreactivity, and specific activity. We adhere to relevant guidelines for the handling of radioactive pharmaceuticals.

Storage

Preserve in a tightly closed container, protected from light. Due to its radioactive nature and chemical properties, including being easily oxidized, this material must be stored under appropriate conditions as defined by radiation safety protocols. Specific storage temperature and shielding requirements are provided with the product and must be strictly followed. Handle and store in accordance with all local, state, and federal regulations for radioactive materials.

Specification

Item	Specification
Appearance	Clear, colorless to slightly yellow solution
Identification (HPLC/Radio-TLC)	Conforms to reference standard
Radiochemical Purity (HPLC)	≥ 95%
Specific Activity	Provided on COA (mCi/mg)
Immunoreactive Fraction	> 70%
pH	6.0 - 7.5
Endotoxin	< 5.0 EU/mL
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.